Olaparib tablet formulation: Effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 4, 2015, Pages 723-729

  Plummer, Ruth ^a   Swaisland, Helen ^b   Leunen, Karin ^c   Van Herpen, Carla M L ^d   Jerusalem, Guy ^e   De Grève, Jacques ^f   Lolkema, Martijn P ^g   Soetekouw, Patricia ^h   Mau Sørensen, Morten ⁱ   Nielsen, Dorte ^j   Spicer, James ^k   Fielding, Anitra ^l   So, Karen ^l   Bannister, Wendy ^m   Molife, L Rhoda ⁿ  

^a Northern Centre for Cancer Care   (United Kingdom)

^b Therakin Consulting   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ Rigshospitalet   (Denmark)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k GUY S HOSPITAL   (United Kingdom)

^l ASTRAZENECA   (United Kingdom)

^m PHASTAR   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

Food effect; Olaparib; PARP inhibition; PK; Tablet

Indexed keywords

OLAPARIB; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; TABLET;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL EVALUATION; COLORECTAL CANCER; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ELIMINATION HALF-LIFE; FATIGUE; FEMALE; FOOD DRUG INTERACTION; HEADACHE; HEMOPTYSIS; HUMAN; LIPID DIET; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; OPEN STUDY; OVARY CANCER; PATIENT HISTORY OF SURGERY; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH SURGERY; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; VOMITING; ADVERSE EFFECTS; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; HALF LIFE TIME; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; TABLET; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DIET, HIGH-FAT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; TABLETS;

EID: 84942197194     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2836-2     Document Type: Article

References (17)

1. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J (2008) Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14:3916-3925
2. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079-17084
3. Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti PP (2012) Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs 21:1575-1584
4. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-251
5. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244
6. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, MacPherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852-861
7. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2014) Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol. doi: 10.1200/JCO.2014.56.2728 (Nov 3 [Epub ahead of print])
8. Oza A, Cibula D, Benzaquen AO, Poole C, Mathijssen RHJ, Sonke GS, Colombo N, Spacek J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe E, Dougherty B, Barrett JC, Friedlander M (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16:87-97
9. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira Frommer R, Safra T, Matei D, MacPherson E, Watkins C, Carmichael J, Matulonis U (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382-1392
10. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett J, Matulonis U (2014) Randomized trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis by BRCA mutation status. Lancet Oncol 15:852-861
11. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134
12. Molife R, Kaye S, Forster M, Ransom M, Greystoke A, Middleton M, Pwint T, McCormack P, Swailand H, Carmichael J (2010) A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors. J Clin Oncol 28(7S):abst 2599
13. Mateo J, Friedlander M, Sessa C, Leunen K, Nicum S, Gourley C, Fielding A, Bowen K, Kaye S, Molife LR (2013) Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation. Eur J Cancer 49(2 Suppl):abst 801
14. Molife LR, Mateo J, McGoldrick T, Krebs M, Drew Y, Banerjee SN, Nicum S, Ranson M, Rustin GJ, Sessa C, Plummer R, Leunen K, Friedlander M, Swaisland H, Burke W, McCormack P, Pemberton K, Tchakov I, Kaye SB, Gourley C (2012) Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations. J Clin Oncol 30(15S):abst 3048
15. AstraZeneca. Global policy: bioethics. 2015. http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies
16. U.S. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies. FDA
17. Rolfo C, Swaisland H, Leunen K, Rutten A, Soetekouw P, Slater S, Verheul HM, Fielding A, So K, Bannister W, Dean E (2015) Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv Ther 32:510-522